Skip header and navigation

Refine By

   MORE

1 records – page 1 of 1.

Randomized controlled intervention in cardiovascular drug treatment in nursing homes.

https://arctichealth.org/en/permalink/ahliterature71234
Source
Pharmacoepidemiol Drug Saf. 2003 Oct-Nov;12(7):589-93
Publication Type
Article
Author
Johanna Ulfvarson
Johanna Adami
Bengt Ullman
Regina Wredling
Marie Reilly
Christer von Bahr
Author Affiliation
Department of Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Stockholm Söder Hospital, Institution for Nursing, Sweden.
Source
Pharmacoepidemiol Drug Saf. 2003 Oct-Nov;12(7):589-93
Language
English
Publication Type
Article
Keywords
Activities of Daily Living
Aged
Aged, 80 and over
Cardiovascular Agents - administration & dosage
Cardiovascular Diseases - drug therapy - pathology
Female
Health Services for the Aged
Homes for the Aged
Humans
Male
Medical Audit
Nursing Homes
Physician's Practice Patterns
Quality of Life
Sweden
Treatment Outcome
Abstract
OBJECTIVE: To study drug treatment of patients with cardiovascular diseases (heart failure, post-myocardial infarction, angina pectoris, hypertonia or cardiac valvular disease) in nursing homes and assess effect of medication advice. INTERVENTION: The patients were randomized to an intervention or control group. Medication reviews were made by one specialist in clinical pharmacology and one in cardiology. Symptoms related to heart failure or adverse reactions to cardiovascular drugs were recorded using a questionnaire. Quality of life and activities of daily living (ADL) were assessed and follow-ups performed after 2 weeks and 3 months. Outcome measures were changes of drug therapy and the global scores computed from symptoms scales. RESULTS: Eighty patients were randomized. They had a mean age of 87 years and their average number of drugs was 9.6. Changed drug therapy was suggested in 40 patients and the advice was followed by the responsible physicians in 19 patients. The physicians mostly followed advice for changed furosemide therapy but not for introducing an ACE-inhibitor, probably due to uncertain diagnosis and need for follow-up after initiation of such therapy. No significant changes from baseline to later follow-up were found in the mean total scores of any questionnaire. CONCLUSION: Intervention did not affect cardiovascular symptoms. Drug revisions should involve more than one class of drugs in order to be cost-effective.
PubMed ID
14558182 View in PubMed
Less detail